Sintilimab, the Revolutionary Chinese’s Anti-Cancer Drug
Chinese drug Sintilimab, an anti-PD-1 drug, was designed for treating relapsed/refractory (the reappearance of a disease which regrows again after complete or partial remission) Hodgkin lymphoma. It has recently won international recognition for its high rate of success in China.
An Emerging Treatment For Hodgkin Lymphoma
Hodgkin Lymphoma occurs mostly in young people between the ages of 20 to 40, and is a rare malignant lymphoma. The cure rate of the disease is high when it is treated early, however, there is a 20% chance of recurrence after the first treatment. 80.4% of patients who had relapsed/refractory Hodgkin lymphoma, showed a decrease in tumour size after treatment with Sintilimab.
Boosting Immune System for Helping Cancer Patients
Sintilimab is an emergency anti-cancer treatment. It helps boost the immune system of a patient, which helps the body in targeting and killing tumours. Sintilimab shows more successful results compared to other immune booster supplements.
Anti-Cancer Drugs for Medical Insurance Coverage in China
As of October 2018, Chinese health insurance includes 17 anti-cancer drugs for cancer treatment to the list of items that are eligible for reimbursement. This allows more people than ever to have financial access to potentially lifesaving treatment which otherwise would have been to expensive. Thanks to top cancer research, more medicines are being considered to be added to this list.